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The Effects of Medications on Myocardial Perfusion
Gilbert J. Zoghbi, MD, FACC, Todd A. Dorfman, MD, Ami E. Iskandrian, MD, MACC
Birmingham, Alabama
Antianginal and lipid-lowering medications may modify the results of stress myocardial perfusion imaging. Sev-
eral studies have shown the beneficial potential of these agents in suppressing myocardial ischemia in patients
with known coronary artery disease. The effects of nitrates, calcium-channel blockers, beta-blockers, and statins
on myocardial perfusion imaging are likely attributable to changes in myocardial blood flow and myocardial oxy-
gen supply–demand ratio. This comprehensive review examines relevant experimental and clinical published
data. Technical issues in image interpretation specific to myocardial perfusion imaging and implications of use
of cardiac medications to results of myocardial perfusion imaging are discussed. (J Am Coll Cardiol 2008;52:
401–16) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.035v
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atress myocardial perfusion imaging (MPI) is widely used
or the diagnosis and risk assessment of patients with known
r suspected coronary artery disease (CAD) (1). Also, MPI
ends itself to monitoring the effects of therapeutic inter-
entions such as anti-ischemic medications, gene therapy,
nd various percutaneous and surgical revascularization
odalities.
This review focuses on the effects of medications on stress
PI. Anti-ischemia medications may decrease the size of
he perfusion defects, cause false-negative results, and de-
rease the diagnostic accuracy of the test. On the other
and, improvement in perfusion pattern has been associated
ith a decrease in the risk of cardiac death or myocardial
nfarction, especially in patients with a severely abnormal
aseline study (2).
Lipid-lowering and antianginal medications, such as
alcium-channel blockers (CCBs), beta-blockers (BBs), and
itrates, have been shown to improve the perfusion pattern
Tables 1 to 3). The studies in support of this statement are
f 2 types: 1) parallel studies of patients on therapy
ompared with patients not on such therapy; and 2) serial
tudies of patients before and after treatment. The first type
f studies suffers from important differences in patients’
haracteristics in the 2 groups, is not helpful in elucidating
he true effects, and will only be cited briefly if deemed
ecessary.
The effects of commonly used medications in patients
ith CAD on MPI may be secondary to their effects on
yocardial blood flow (MBF), tracer kinetics, or myocardial
xygen demand (3–5). In addition, a host of technical
rom the Division of Cardiovascular Diseases, Department of Medicine, The
niversity of Alabama at Birmingham, Birmingham, Alabama. Drs. Zoghbi and
orfman contributed equally to this article.s
Manuscript received March 19, 2008; revised manuscript received April 14, 2008,
ccepted April 21, 2008.ariables related to image acquisition and interpretation may
e important (3–5). There are no data to indicate that
itrates, CCBs, BBs, and statins affect tracer kinetics apart
rom their indirect effect on MBF (3–5). It is conceivable
hat the size and severity of perfusion defects is modified
ecause of changes in the degree of partial volume effect in
he presence of regional wall motion abnormalities, for
xample, myocardial stunning or hibernation and subse-
uent amelioration of ischemia. Clearly more data are
eeded. The results of studies that evaluated the effects of
ntianginal medications and statins on stress MPI in hu-
ans are summarized in Tables 1 to 3. The results of
xperimental studies are summarized in Table 4. Before we
iscuss the effects of medications, we need to address the
echnical issues related to imaging.
echnical Issues in Image
nterpretation Specific to MPI
omparing 2 sets of images in the same patient by visual
nalysis or by using automated programs is more difficult
han realized, and the reasons have recently been summa-
ized (Table 5) (6). Absolute quantification (ml/g/min)
llows a more precise assessment of serial changes, but such
nalysis is not yet possible by MPI, and it may be that the
etection of small changes is difficult even with the more
bsolute quantitative methods because of considerable in-
erpatient variability. Knowing the inherent variability of
ingle-photon emission computed tomography (SPECT)
maging is critical to determine whether observed changes in
can interpretation can be ascribed to actual changes due to
reatment, changes in the patients’ condition, or procedure
ariability (6). There are few previous studies evaluating
greement rates for sequential imaging. These studies were
ingle center and included small numbers of patients.
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compared inter-reader interpre-
tation of a single image and not 2
sequential images; agreement
rates for comparison of sequen-
tial images may be lower because
acquisition of a second image
introduces biological changes,
medication effect, and technical
variability in acquisition, pro-
cessing, and interpretation of the
images. The analysis often used
sample-weighted averages to cal-
culate agreement rates, which
gives the category with the high-
est number of patients the great-
est contribution to the average.
Finally, agreement rates are usu-
ally reported for the overall im-
pression of the scan as normal
versus abnormal or normal versus
ischemia versus infarct; it is well
known that agreement rates are
etter when categories are narrow rather than wide, such as
xtent and severity of ischemia (7,8).
itrates
xperimental studies. All forms of nitroglycerin prepara-
ions release nitric oxide in vascular smooth muscle cells (9).
itric oxide activates soluble guanylyl cyclase, leading to the
roduction of guanosine 3,5-cyclic monophosphate
cGMP) that facilitates smooth muscle cell relaxation
hrough the dephosphorylation of myosin light chains. This
nhibits the interaction between myosin and actin and
revents smooth muscle contraction (10). Nitroglycerin
auses marked relaxation of all components of the vascular
ystem and dramatically decreases pulmonary vascular pres-
ure, intraventricular pressure, chamber size, and cardiac
utput (10). Nitroglycerin therefore may improve myocar-
ial perfusion via a reduction in wall tension (Laplace
elation) and myocardial oxygen demand (10–12).
Nitroglycerin decreases coronary vascular resistance and
ncreases the diameter of large conduit vessels (100 m);
he degree of smaller vessel dilation exceeds that of larger
essels only after the highest doses of nitroglycerin (13).
owever, total coronary flow does not increase in the
resence of obstructive CAD (10,13–17). Nitroglycerin
electively dilates microvessels distal to coronary stenosis,
ut myocardial perfusion remains constant (17). The anti-
schemic effect of nitroglycerin might also be attributable to
he redistribution of coronary flow from normal to ischemic
yocardium through dilation of collateral vessels (10,11,18).
Nitroglycerin may also preserve myocardial perfusion
Abbreviations
and Acronyms
BB  beta-blocker
CAD  coronary artery
disease
CCB  calcium-channel
blocker
CFR  coronary flow
reserve ratio
LDL  low-density
lipoprotein
MBF  myocardial blood
flow
MPI  myocardial perfusion
imaging
PCI  percutaneous
coronary intervention
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomographyhrough the inhibition of platelet thrombus formation o19–22). Nitric oxide is capable of activating soluble gua-
ylyl cyclase in platelets. This stimulates cGMP production
nd inhibits thrombin-induced platelet aggregation to aden-
sine diphosphate by approximately 80% (21), and it de-
reases platelet aggregation to thrombin (22). Nitric oxide
lso up-regulates endothelial cell cyclo-oxygenase activity,
esulting in a marked increase in the release of the stable
etabolite of prostaglandin I2, 6-keto prostaglandin
1alpha, and this metabolite enhances the antithrombotic
ffects of nitrates by approximately 10-fold (21). Continu-
us nitroglycerin infusion markedly decreases platelet
hrombus formation without affecting coronary flow (19).
he antiplatelet effects are subject to tolerance (23).
linical studies. The effects of nitrates on MPI were
tudied with different nitroglycerine doses and modes of
dministration (Table 1). Earlier studies used exercise pla-
ar imaging (21), but later studies used SPECT (24,25).
he study designs varied from comparison of studies before
nd after treatment (24,26,27), a crossover study (28), and
andomized, double-blind, placebo-controlled studies (25,29).
The acute administration of sublingual (24) or short-
cting nitrates (25) significantly decreased the ischemic
erfusion severity or size in the culprit zone compared with
lacebo (25) or with a baseline study without nitrates (24).
imilarly, the chronic administration of long-acting nitrates
ecreased ischemia severity (27) and perfusion defect size
26,29) compared with placebo (29) or with a baseline study
ithout nitrates (26,27). The improvement in perfusion was
reater in patients with large baseline defects than in those
ith small defects and was independent of changes in heart
ate or blood pressure, suggesting that the improvement was
ostly attributable to enhancement of MBF (29). In a small
tudy of 15 patients, treatment with nitroglycerin patches
or 4 weeks decreased the extent of ST-segment depression
ut did not influence the perfusion defect severity (28).
In summary, acute or chronic administration of nitrates
as been shown to decrease the size and severity of exercise-
nduced myocardial perfusion defects.
ffects of nitrates on myocardial viability. Nitrates have
een used in rest studies to enhance the ability of MPI to
etect viable myocardium because they decrease myocardial
xygen demand and improve flow to ischemic areas (by
irectly dilating stenosed coronary arteries feeding the
schemic myocardium or by redistributing collateral flow to
he ischemic myocardium) (24,30). In positron emission
omography (PET) studies, pre-treatment with nitrates
ncreased tracer uptake in the ischemic myocardium com-
ared with that in the nonviable myocardium, resulting in
mproved viability detection (31,32). Pre-treatment with
itrates improved detection of viable myocardium and
redicted post-revascularization recovery in different studies
hat used resting MPI with the technetium-labeled tracers
tetrofosmin, sestamibi) and with thallium-201 (33–40). In
atients with ischemic cardiomyopathy, the prognostic
alue of SPECT MPI after nitrate was comparable to that
f PET imaging (40).
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xperimental studies. The major anti-ischemic effect of
Bs is a reduction in myocardial oxygen consumption both
t rest and during stress (12,41,42). Beta-blockers decrease
yocardial oxygen demand through a reduction in heart
ate, blood pressure, and myocardial contractility. They also
rolong diastole, therefore increasing coronary perfusion time
10,41).
Beta-blockers improve ischemic wall function and pre-
erve regional blood flow, but the benefit of BBs was
egated when heart rate reduction was eliminated (41).
owever, BBs significantly increase myocardial oxygen
xtraction and markedly decrease myocardial oxygen con-
umption in ischemic regions by improving microregional
istribution of blood flow within the ischemic zone (43).
eta-blockers increase the endocardial-to-epicardial flow ratio,
BF/beat, and relative MBF in ischemic areas (43,44).
Alteration in cardiomyocyte metabolism provides an ad-
itional cardiovascular protection against ischemia (45). In a
odel of coronary occlusion, metoprolol significantly re-
ummary of Studies That Evaluated the Effects of Antianginal Med
Table 1 Summary of Studies That Evaluated the Effects of Anti
Author, Year (Ref. #) Patients
Nitrates
Eldridge et al., 1987 (28) 15 patients with stable angina
and CAD on angiography or
abnormal stress MPI
Exercise thallium SPECT
NTG pa
(70 m
Antiang
test
Crossov
Aoki et al., 1991 (24) 7 patients with total or
subtotal proximal LAD
occlusion and well-
developed collaterals
Exercise thallium SPECT
0.3 mg
befo
Mahmarian et al., 1994 (29) 40 patients with stable
angiographic CAD and no
prior MI perfusion defects
involving 5% of the left
ventricle
Exercise thallium SPECT
Intermi
(0.4
Most pa
med
Random
place
Goller et al., 1995 (25) 30 patients with stable angina
and 70% stenosis
Exercise Tc-99m SPECT
60 mg
nitra
testi
Antiang
2 to
Random
cont
Lewin et al., 2000 (26) 40 patients with chronic stable
angina and 10%
reversible defect of any
coronary vascular territory
at baseline
Exercise dual-isotope SPECT
Isosorb
4 da
42 d
Off anti
befo
mon
testsuced infarct size and markedly increased coronary collat- aral flow compared with placebo (45). Metoprolol, unlike
lacebo, reduced myocardial oxygen consumption and
aintained myocardial uptake of lactate and nonesterified
atty acids (45). Beta-blockers also protect against ischemia
nd reperfusion by other mechanisms such as preserving
embrane phospholipids, decreasing apoptosis, preserv-
ng electrical potential, and enhancing mitochondrial
unction (46–49).
linical studies. Nonrandomized studies compared the
xercise MPI results of patients on with those not on BB
herapies. However, these studies were in different groups of
atients and overall showed a decrease in the sensitivity in
etecting CAD in patients on BBs (50,51).
Different doses, types, and modes of administration were
sed to study the effects of BBs on exercise or dobutamine
PI in the same patients while on or off BBs or in
cross-over study design or a randomized, double-blind,
lacebo-controlled study design (Table 1).
The chronic administration of oral propranolol in pa-
ients undergoing exercise planar MPI improved tracer
ns on MPI
al Medications on MPI
Treatment Testing Perfusion
Perfusion defect score
16 cm/day) or nifedipine
y) for 4 weeks
edication withheld before
y
NTG patch 
NTG patch 
No difference with and
without NTG
Total defect size
gual NTG a few minutes NTG 
NTG 
23  17%
7  9% (p  0.05)
Ischemic defect size
2 h on/off) NTG patch
placebo
weaned off antianginal
before test
double-blind, parallel,
ntrolled
Placebo:
baseline and
at 6.1 
1.8 days
Patch: baseline
and at 6.1 
1.8 days
12.3  10.0% to
11.3  12.2%
18.6  10.1% to
10.1  10.5%, p  0.04
Ischemic defect size
ed release isosobide-5-
inistered 5 h before
edication withheld for
before test
double-blind, placebo-
tudy
Placebo
(baseline
treatment)
Nitrates
(baseline
treatment)
35.2  27.6% to
36.6  27.4% (p  NS)
38.2  31.0% to
29.1  33.8% (p  0.05)
Total perfusion defect
size/SSS
nonitrate 60 mg daily for
120 mg daily for 35 to
l medications for 24 h
(except isosorbide
e for second and third
Baseline
5 days
35 to 42 days
34.9  12.2%/20  10
—/18  10
30.1  12.7%/17  10
(p  0.002)
Continued on next pageicatio
angin
tches (
g/da
inal m
er stud
sublin
re test
ttent (1
mg/h)
tients
ication
ized,
bo-co
sustain
te adm
ng
inal m
3 days
ized,
rolled s
ide mo
ys and
ays
angina
re test
onitrat
)ctivity compared with placebo or with baseline studies
C
n
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Table 1 Continued
Author, Year (Ref. #) Patients Treatment Testing Perfusion
Beta-blockers Defect mass: exercise and
redistribution
Narahara et al., 1989 (54) 12 patients with chronic stable
angina and CAD
Exercise thallium SPECT
Randomization to propranolol 40 mg 4
times daily or betaxolol 20 mg/day
for 2 weeks
Placebo for 5 weeks
Beta-blockers were held for 48 h and
calcium-channel blockers for 24 h
before each test
Randomized, placebo-controlled
Placebo
Beta-blocker
47  36.3 g and 28  29.8 g
32  27.1 g and 15  23.3 g
(p  0.01 for both defects)
Defect size
Bridges et al., 1992 (56) 12 patients with CAD on
angiography
Dipyridamole thallium SPECT
Atenolol 50 mg/day for 1 week
Placebo for 1 week
Randomized, double-blind and
crossover study
Atenolol vs.
baseline
Placebo vs.
baseline
No difference
No difference
SSS and SDS
Shehata et al., 1997 (55) 17 patients with ischemia on
prior MPI
Dobutamine Tc-99m SPECT
Intravenous propranolol to a
cumulative dose of 8 mg or to a
maximum baseline heart rate
reduction of 25%
Beta-blockers and calcium-channel
blockers held 48 and 24 h before
test, respectively
Propranolol 
Propranolol 
14  9 and 7  6
(p  0.02 for SSS)
18  10 and 10  7
(p  0.047 for SDS)
CFR
Bottcher et al., 1997 (58) 10 healthy volunteers
Dipyridamole NH3-PET
Metoprolol 50 mg orally 12 and 1 h
before the study
Metoprolol 
Metoprolol 
3.14  0.80
4.61  0.68 (p  0.01)
SSS and SDS
Taillefer et al., 2003 (57) 21 patients with
catheterization-proven
stable CAD
Dipyridamole Tc-99m SPECT
Acute administration of placebo, low-
dose (up to 10 mg) and high-dose
(up to 20 mg) intravenous
metoprolol
Beta-blockers and calcium-blockers
held 48 and 24 h before test,
respectively
Prospective, randomized, double-blind,
placebo-controlled
Placebo
Low-dose
metoprolol
High-dose
metoprolol
12.0  10.1 and 8.4  8.8
8.7  9.0 and 5.0  6.7
(p  0.05) vs. placebo
9.3  10.6 and 5.4  7.9
(p  0.05) vs. placebo
CFR
Bottcher et al., 2003 (60) 14 patients with angiography-
proven CAD (70% stenosis)
Dipyridamole NH3-PET
Metoprolol 50 mg/day
Off antianginal medications
(5 half lives)
Randomized
Metoprolol 
Metoprolol 
2.16  0.56
1.87  0.55 (p  NS)
CFR in stenotic and remote
segments
Koepfli et al., 2004 (42) 36 patients with
angiographically-
documented CAD and
stable angina
Adenosine NH3-PET
12 weeks treatment with beta-blockers
(100 mg metoprolol/day or 50 mg
carvedilol/day)
Antianginal medication held for
1 week before test
Double-blind design
Beta-blocker 
Beta-blocker 
2.23  0.88 and 2.39  0.83
2.62  1.10 and 2.64  0.75
(p  0.05 for stenotic and
p  NS for remote
segments)
Calcium-channel blockers Perfusion defect score
Eldridge et al., 1987 (28) 15 patients with stable angina
and CAD on angiography or
abnormal stress MPI
Exercise thallium SPECT
NTG patches (16 cm/day) or nifedipine
(70 mg/day) for 4 weeks
Crossover study
Nifedipine 
Nifedipine 
49  28
28  26 (p  0.01)
Percent thallium uptake: MI
and angina
Yamazaki et al., 1993 (69) 12 patients with prior MI and
9 patients with angina
pectoris
Exercise thallium SPECT
Nicorandil 15 mg/day for at least
3 weeks
Nicorandil 
Nicorandil 
52.4% and 56.9%
60.4% and 69.1%
(p  0.05 for MI and angina
patients)
p  0.05 for difference between groups.
CAD  coronary artery disease; CFR  coronary flow reserve ratio; LAD  left anterior descending; MI  myocardial infarction; MPI  myocardial perfusion imaging; NS  not significant; NTG 
itroglycerin; PET  positron emission tomography; SDS  summed difference score; SPECT  single-photon-emission computed tomography; SSS  summed stress score; Tc  technetium.
w
w
r
t
p
r
w
s
r
w
m
p
b
s
n
p
S

eft ven
p Tl  th
405JACC Vol. 52, No. 6, 2008 Zoghbi et al.
August 5, 2008:401–16 Effects of Medications on Myocardial Perfusionithout BBs (52,53). The patients exercised to the same
ork load before and after treatment, although their heart
ates were lower (53). Intravenous propranolol administra-
ion to patients undergoing exercise MPI also decreased the
erfusion defect size compared with placebo (50); the
eduction in defect size was noted in the subgroup of patients
ho achieved the same double product with propranolol,
uggesting that the effect may not entirely be related to the
ummary of Studies That Evaluated the Effects of Statins on SPEC
Table 2 Summary of Studies That Evaluated the Effects of Stat
Author, Year (Ref. #) Patients Treatm
Eichstadt et al., 1995 (100) 17 patients, high
cholesterol, angina,
and abnormal
exercise
Tl-SPECT
Fluvastatin 40 mg 4
6 weeks, increase
twice daily if LDL
30%
Eichstadt et al., 2000 (101) 22 patients, high
cholesterol, angina,
and abnormal
exercise
Tl-SPECT
Fluvastatin 40 mg 4
6 weeks, increase
twice daily if LDL
30%
Hosokawa et al., 2000 (102) 50% CAD  prior MI
or angina with
abnormal exercise
Tl-SPECT:
Statin group: 15
patients
Control group: no lipid
lowering
Statin group: simvas
times daily
Control group: no lip
Mostaza et al., 2000 (93) 20 patients with at least
1 vessel with
50% diameter
stenosis, prior MI or
stable angina with
abnormal
dipyridamole
Tl-SPECT, and
average cholesterol
on no lipid-lowering
drugs (placebo-
controlled with
crossover design)
Pravastatin 20 mg 4
16 weeks
Placebo for 16 week
Schwartz et al., 2003 (104) 25 patients with LDL
130 mg/dl, clinical
CAD, and abnormal
stress MPI underwent
exercise or adenosine
SPECT MPI at
baseline, 6 weeks,
and 6 months after
lipid lowering
Pravastatin 40 mg 4
6 months
Manfrini et al., 2004 (103) Post–single-vessel PCI
with cholesterol
220 and not on
antilipid drugs
Pravastatin 40 mg 4
6 months
Placebo
p  0.05 for difference between groups.
DM  diabetes mellitus; HDL  high-density lipoprotein; LDL  low-density lipoprotein; LV  l
ercutaneous coronary intervention; SRS  summed rest score; TET  treadmill exercise testing;eduction in myocardial oxygen demand (50). lSimilar BB effects were observed in patients who under-
ent exercise or dobutamine SPECT MPI. Chronic treat-
ent decreased the rest and exercise defect severity com-
ared with placebo (54). Acute propranolol administration
efore dobutamine MPI decreased the defect size and
everity compared with the study without propranolol and
ormalized the scans in 23% of patients (55). The double
roduct was significantly lower after intravenous proprano-
I
n SPECT MPI
Cholesterol Change (mg/dl) Perfusion
daily for
0 mg
se
LDL 191  26 (baseline)
LDL 146  28 (12 weeks)
(p  0.001)
Counts per matrix at 12 weeks:
1 30% in ischemic segments
(p  0.001)
1 5% in normal segments
(p  0.005)
daily for
0 mg
se
LDL 196 (baseline)
LDL 145 (12 weeks) (p  0.001)
LDL 148 (24 weeks)
Counts per matrix at 12 weeks:
1 26% in ischemic segments
(p  0.001)
1 4% in normal segments
(p  0.01)
Counts per matrix at 24 weeks:
1 29% in ischemic segments
(p  0.001)
1 4.4% in normal segments
(p  0.01)
mg 4
ring
Statin group:
Non-HDL 197.7  5.6 (baseline)
Non-HDL 146.5  5.7 (1 yr)
(p  0.05)
Control group: Non-HDL 184.9 
9.0 (baseline)
Non-HDL 194.3  8.8 (1 yr)
(p  0.05)
Statin group:
SSS 15.8  3.6
SRS 13.1  3.4 (baseline)
SSS 11.7  3.3
SRS 9.7  3.0 (1 yr)
(p  0.01)
Control group:
SSS 13.4  3.2
SRS 12.0  2.8 (baseline)
SSS 14.6  2.0 (p  0.05)
SRS 12.9  2.2 (1 yr)
daily for LDL 103  23 after pravachol
LDL 148  25 after placebo
(p  0.0001)
SSS 5.9  2.3 SDS 2.4  2.2
SSS 7.2  2.3 SDS 3.2  1
(p  0.043)
p  0.012 for SSS and
p  0.043 for SDS
daily for LDL 134  31 at baseline
91  18 at 6 weeks (p  0.05
vs. baseline)
96  23 at 6 months (p  0.05
vs. baseline)
SDS and percent LV perfusion
defect
8.3  4.6% and 25.5  13.7%
at baseline
6.5  7.2% and 24.5  14.1%
at 6 weeks
5.0  8.0% and 16.6  13.8%
at 6 months
(p  0.05 vs. baseline)
daily for LDL 114  17 to 101  12
(p  0.05)
LDL 113  7 to 113  18
SDS 7.7 2.8 at baseline
to 0.3 1.5*
SDS 7.8  2.7 at baseline
to 3.9  4.4
tricular; MBP  myocardial blood flow; NCEP  National Cholesterol Education Program; PCI 
allium; other abbreviations as in Table 1.T MP
ins o
ent
times
d to 4
decrea
times
d to 4
decrea
tatin 5
id lowe
times
s
times
timesol despite higher infusion dobutamine doses (55).
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PECT MPI was assessed in a randomized, double-blind,
rossover study that showed no difference in the perfusion
efect size and severity between placebo and atenolol for the
roup as a whole, although one-third of patients had larger
efects on atenolol than placebo (56). The acute adminis-
ration of metoprolol before dipyridamole MPI decreased
he sensitivity of CAD detection from 86% to 71% and
educed the extent and severity of ischemia by 25% to 30%
ompared with placebo (57).
ffects of BB on MBF. Because the effects of medications
n myocardial perfusion might be explained by their effects
n MBF, studies that examined such effects with either
he PET or Doppler-wire method warrant a short discus-
ummary of Studies That Evaluated the Effects of Statins on PET M
Table 3 Summary of Studies That Evaluated the Effects of Stat
Author, Year (Ref. #) Patients Treatm
Gould et al., 1994 (105) 12 patients with 1 vessel
CAD (50% diameter
stenosis), stable angina,
positive TET, and LDL
150 mg/dl
Dipyridamole NH3-PET
3 months of N
2 diet and
lovastatin t
and 1 pack
cholestyram
fat enteral
total paren
nutrition (li
solution)
Huggins et al., 1998 (112) 12 patients with ischemic
heart disease and
without tobacco abuse
or DM
Adenosine NH3-PET
Simvastatin 4
for 4.8 mo
Baller et al., 1999 (113) 23 patients with angina,
minimal CAD, elevated
LDL, and abnormal CFR
by dipyridamole NH3-PET
Simvastatin 2
4 times da
6 months
Guethlin et al., 1999 (114) 15 patients with
angiographically
documented multivessel
CAD and LDL 160
mg/dl
Adenosine NH3-PET
Fluvastatin 60
mg/day fo
6 months
Yokoyama et al., 1999 (115) 27 hypercholesterolemic
patients with 1 normal
coronary artery on
angiography
Dipyridamole NH3-PET
Lipid-lowering
8 to 15 mo
Yokoyama et al., 2001 (116) 16 patients with familial
hypercholesterolemia, no
known CAD or angina
symptoms, and
normal TET
Dipyridamole NH3-PET
Simvastatin 5
mg/day fo
months
Ling et al., 2005 (117) 72 patients with CAD and
elevated LDL
Dipyridamole Rb-PET
Simvastatin 2
4 times da
(n  23) fo
Pravastatin 4
4 times da
(n  24) fo
Placebo (n 
p  0.05 for difference between groups.
MBF  myocardial blood flow; other abbreviations as in Tables 1 and 2.ion (Table 1). mThe acute administration of metoprolol (50 mg orally
iven 12 h and 1 h before the study) before dipyridamole
H3-PET decreased resting MBF and increased hyper-
mic MBF, resulting in a significant increase in the coronary
ow reserve ratio (CFR) compared with no BB administra-
ion (58). The chronic administration of BB increased CFR
n stenotic vessels, but it did not affect the CFR in normal
egments during adenosine NH3-PET (42). In an angio-
lasty model that used a Doppler wire to measure CFR,
re-treatment with intravenous metoprolol increased post-
schemic CFR (after 1 min of balloon occlusion) and
ost-adenosine CFR compared with no metoprolol pre-
reatment (59).
Bottcher et al. (60) studied the effects of nitroglycerin,
n PET MPI
Cholesterol Change Perfusion
tep
aily
o-
r
e
LDL (mg/dl)
213  79 pre-treatment
(p  0.01)
151  59 post-treatment
207  67 post-washout (p  0.01)
Dipyridamole/rest normalized
counts
Percent 2.5 SD:
22  20% pre-treatment
(p  0.02)
13  14% post-treatment
26  22% post-washout
period (p  0.009)
day LDL (mg/dl)
171  13 at baseline
99  18 at 4.8 months
(p  0.001)
Hyperemic MBF of abnormal
segments
1.8  0.5 at baseline
2.5  1.0 at 4.8 months
(p  0.01)
LDL (mg/dl)
165  34 at baseline
95  26 at 6 months
CFR 2.2  0.6 at baseline to
2.64  0.6 (p  0.01)
LDL (mg/dl)
181  20 at baseline
114  14 at 2 months (p  0.05)
113  17 at 6 months (p  0.05)
Global CFR
2.5  0.6 at baseline
2.7  0.9 at 2 months
(p  NS vs. baseline)
3.4  1.0 at 6 months
(p  0.05 vs. baseline)
for LDL (mg/dl)
173  34.8 at baseline
123  23.0 mg/dl at 8 to 15
months (p  0.01)
CFR of normal coronary
arteries
2.25  0.77 at baseline
3.27  1.69 at 8 to 15
months (p  0.01)
5
Total cholesterol (mg/dl)
277  49 at baseline
205  40.3 at 9 to 15 months
(p  0.01)
Global CFR
2.27  0.63 at baseline
3.33  1.19 at 9 to 15
months (p  0.01)
eks
eks
LDL (mmol/l)
3.52  0.6 to 1.88  0.48
(p  0.001)
3.5  0.7 to 2.3  0.6
(p  0.001)
3.5  0.5 to 3.8  0.7
Global flow reserve/
segmental flow reserve
2.1  0.6 to 1.9  0.8/
1.7  0.6 to 1.7  0.9
2.3  1.1 to 1.6  0.8/
1.8  0.7 to 1.8  0.6
2.1  0.6 to 2.3  0.7/
1.8  0.6 to 2.1  0.7PI
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August 5, 2008:401–16 Effects of Medications on Myocardial Perfusionatients with severe CAD (70% stenosis) who randomly
nderwent dipyridamole MPI with NH3-PET while on
nd off medications (5 half lives). Nitroglycerin (n  25)
ncreased the resting MBF. Unlike the prior studies, this
tudy showed that BBs (n  14) decreased the resting and
yperemic MBF in stenosis and normal segments with no
hange in CFR (60). Calcium-channel blockers (10 pa-
ients) did not have a significant effect on resting or
ipyridamole-induced hyperemic MBF (60). In contrast,
ummary of Experimental Data of Effects of Nitrates, Beta-Blocker
Table 4 Summary of Experimental Data of Effects of Nitrates, B
Author, Year (Ref. #) Study
Nitrates
Cohen et al., 1973 (18) Effect on myocardial function in dogs after coron
Macho et al., 1981 (15) Effect of coronary occlusion in dogs on flow, diam
resistance
Habazettl et al., 1990 (13) Effect in dogs on coronary microvessel diameter
Kanatsuka et al., 1992 (17) Effect in dogs on microcirculation in ischemic zon
Lacoste et al., 1994 (22) Effect in pigs on thrombus formation
Salvemini et al., 1996 (21) Effect in rats on in vivo thrombin-induced platelet
Folts et al., 1991 (19) Effect in dogs on platelet thrombus formation in
stenosis
Muller et al., 2004 (118) Effect in rabbits on aortic vascular superoxide, in
formation, and vasoreactivity
Calcium-channel blockers
Reimer et al., 1985 (64) Myocardial protection in dogs after coronary
occlusion/reperfusion
Tillmanns et al., 1991 (63) Effect in rats on microcirculation
Sassen et al., 1991 (65) Effect in pigs on flow with occlusion/reperfusion
Park et al., 1996 (66) Effect in pigs of repetitive ischemia
Ehring et al., 1997 (68) Effect in dogs on myocardial blood flow, function
size with severe coronary stenosis
Folts et al., 1997 (67) Effect in dogs on platelet aggregation
Beta-blockers
Matsuzaki et al., 1984 (44) Effect in dogs with coronary stenosis on exercise-
myocardial ischemia
Grover et al., 1987 (43) Effect in dogs with coronary occlusion on myocar
and demand
Guth et al., 1987 (41) Effect in dogs with coronary stenosis on exercise-
myocardial ischemia and regional dysfunction
Liu et al., 1991 (46) Effect in rats of 3 different beta-blockers on mem
phospholipid integrity after ischemia/reperfus
Feuerstein et al., 1993 (49) Effect in rats, minipigs, and dogs on infarct size
Zmudka et al., 1998 (45) Effect in dogs on myocardial O2 consumption and
after coronary artery occlusion
Schwarz et al., 2003 (48) Effect in rats on infarct size and apoptosis in an i
Monteiro et al., 2003 (47) Effect in rats on mitochondrial function during iscervos et al. (61) reported that nifedipine increased MBF vby PET) in normal segments as well as in segments with
ild, moderate, and severe stenoses, though the improve-
ent was to a lesser extent as stenosis severity increased.
In summary, BBs improve the perfusion pattern of
xercise and dobutamine MPI, but the results are inconsis-
ent with vasodilator MPI. The changes are likely caused by
lterations in MBF. The implication of such results is that
Bs are likely to decrease the sensitivity of exercise or
obutamine MPI, but their effects on the sensitivity of
lcium-Channel Blockers, and Lipid-Lowering Agents
Blockers, Calcium-Channel Blockers, and Lipid-Lowering Agents
Observation
lusion Dilates coronary collaterals and increases collateral flow
nd Increases coronary cross-sectional area, decreases diastolic resistance,
and has greater effect on large coronary arteries
rfusion Decreases resistance and increases large-vessel diameter; small-vessel
dilation exceeds that of larger vessels only after high doses
Dilates coronary microvessels distal to the stenosis, but perfusion
remains constant; overall resistance does not change
Decreases platelet aggregation to ADP and thrombin and decreases
thrombus size
gation Enhances cyclo-oxygenase activity and inhibits platelet aggregation to
adenosine diphosphate by 80%
ry Decreases platelet thrombus formation without affecting coronary flow
esion Inhibits the increase of vascular bioavailability of superoxide, prevents
intimal lesion formation and endothelial dysfunction in
hypercholesterolemia
Reduces infarct size from 34% to 8%, decreases myocardial energy
demand, and prevents depletion of ATP during ischemia
Increases diameter of larger coronary arterioles, increases myocardial
phosphocreatine, and preserves ATP
Increases flow, increases ADP and creatine phosphate, and reduces
Ca2 overload
Attenuates myocardial stunning independent of hemodynamic changes
nfarct Decreases infarct size, improves recovery of stunned myocardium, and
enhances myocardial blood flow
Prevents coronary thrombosis
d Decreases HR, systolic pressure, and ()dP/dt during exercise;
improves function in ischemic zone, and increases endocardial-to-
epicardial flow ratio
supply Improves subendocardial/subepicardial flow ratio in ischemic areas,
increases myocardial O2 extraction, and decreases O2 consumption
in ischemic regions
d Decreases HR and increases ischemic wall function; preserves regional
blood flow
Decreases lipid peroxidation, reduces accumulation of free fatty acids,
decreases myocardial creatine kinase release, enhances recovery of
coronary flow, and preserves membrane phospholipids
Reduces infarct size and inhibits lipid peroxidation in a dose-dependent
manner, suppresses superoxide generation, and scavenges oxygen
free radicals
bolism Reduces infarct size, increases coronary collateral flow, decreases
myocardial oxygen consumption, and preserves myocardial uptake
of lactate and nonesterified fatty acid
model Reduces infarct size and apoptosis
Increases mitochondrial energy charge, preserves electrical potential,
and enhances mitochondrial function
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Effects of Medications on Myocardial Perfusion August 5, 2008:401–16n patient selection (extent and severity of CAD) as well as
he dose of BBs. A reduction in defect size might be more
ommon than complete normalization of the perfusion
attern.
CBs
xperimental studies. The primary benefit of CCBs seems
o be a reduction in myocardial oxygen demand, which is
chieved by decreasing arterial tone, peripheral vascular
esistance, intraventricular pressure, and wall stress (10,62).
Calcium channels consistently open after depolarization,
esulting in an increase in intracellular calcium, which forms
complex with calmodulin, thereby activating myosin light
hain kinase. Activated myosin light chain kinase phosphor-
lates myosin light chains, resulting in myosin–actin inter-
ction, namely smooth muscle cell contraction (10). After
CBs bind to the calcium channel, these channels open
nfrequently and dramatically reduce the influx of intracel-
ular calcium. This results in long-lasting smooth muscle
elaxation, which leads to coronary vasodilation and a
ecrease in systemic vascular resistance. Moreover, cardio-
yocytes depend on intracellular calcium for excitation–
ontraction coupling, and CCBs further reduce oxygen
emand in a dose-dependant manner by decreasing con-
ractility and heart rate (nondihydropyridine CCBs)
10,62).
Calcium-channel blockers also enhance myocardial per-
usion through their effects on myocardial microcirculation
nd metabolism (63,64). They may improve coronary flow
n CAD by selectively dilating larger arterioles (63).
Although CCBs decrease myocardial oxygen demand
ndirectly though a reduction in heart rate and contractility,
hese agents also directly decrease myocardial energy re-
ontinued
Table 4 Continued
Author, Year (Ref. #) Study
Lipid-lowering drugs
Bellosta et al., 1998 (70) Effect in mouse on the activity of MMP-9 in macr
Lefer et al., 1999 (72) Effect in rats on neutrophil-mediated cardiac inju
Fukumoto et al., 2001 (75) Effect in rabbits on interstitial collagen gene expr
MMP levels
Bonetti et al., 2002 (82) Effect in pigs on myocardial perfusion and microv
permeability
Wilson et al., 2002 (80) Effect in pigs on coronary vaso vasorum neovasc
Jones et al., 2002 (77) Effect in mice on endothelial nitric oxide producti
reperfusion
Ikeda et al., 2003 (73) Effect in rats on ischemic and reperfused hearts
PMNs
Boodhwani et al., 2006 (71) Effect in pigs on endothelial function in chronic m
ischemia
Zhao, 2006 (81) Effect in pigs on restoration of blood flow after co
occlusion
DP  adenosine diphosphate; ATP  adenosine triphosphate; Ca2  intracellular calcium; HRuirements (64). Ischemia leads to membrane depolariza- mion and a marked increase in intracellular calcium. This
timulates adenosine triphosphate-consuming enzymes,
axing an already depleted energy reserve (10). However,
CBs increase myocardial phosphocreatine and preserve
denosine triphosphate during ischemia (63). Nisoldipine
ignificantly increases sarcoplasmic reticular intracellular cal-
ium pump activity and slightly augments the rate of intracel-
ular calcium uptake in post-ischemic myocardium (65).
Calcium-channel blockers enhance use of free fatty acids
n reversibly ischemic myocardium and attenuate myocardial
tunning independent of hemodynamic changes (63,66).
re-ischemic nisoldipine administration enhances the re-
overy of stunned myocardium after transient coronary
rtery occlusion. Thus, CCBs may provide cardiovascular
rotection by attenuating calcium overload during ischemia
ndependent of hemodynamic changes (66).
Calcium-channel blockers inhibit platelet aggregation
nd thrombus formation, which may improve myocardial
erfusion (10,62,67). In fact, amlodipine completely pre-
ented coronary platelet aggregation even after epinephrine
dministration in a model of experimental coronary artery
hrombosis (67).
Calcium-channel blockers may potentially increase myo-
ardial perfusion by preventing coronary spasm and by
mproving collateral flow (64). In a canine model of severe
oronary artery stenosis, nifedipine increased coronary flow
n areas of ischemia by combating the antagonism of
lpha-adrenergic coronary vasomotor tone during exercise
68). Another large experimental model demonstrated that
re-treatment with verapamil reduced the size of subendo-
ardial infarcts in the ischemic territory and preserved
egional function (64,68).
linical studies. Different CCB doses, CCB types, and
Observation
es Inhibits MMP-9 activity in a dose-dependent manner
Improves coronary flow, enhances endothelial release of nitric oxide,
and reduces PMN accumulation
and Decreases MMP-1, -3, and -9 expression by macrophages
r Increases myocardial perfusion and preserves microvascular
permeability index independent of lipid lowering
tion Attenuates hypoxia in the coronary artery wall and decreases vaso
vasorum neovascularization in the absence of cholesterol lowering
Increases nitric oxide production and nitric oxide synthase messenger
ribonucleic acid levels, and reduces myocardial necrosis by 40%
ed with Reduces PMN adherence to vascular endothelium and PMN infiltration
into post-ischemic myocardium; improves left ventricular function
dial Improves endothelial dysfunction; increases phosphorylation of Akt,
decreases vascular endothelial growth factor, and increases
expression of endostatin
Increases coronary blood flow, decreases area of no-reflow, and
reduces infarct size
t rate; MMP  matrix metalloproteinasese; PMN  polymorphonuclear leucocytes.ophag
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August 5, 2008:401–16 Effects of Medications on Myocardial PerfusionCBs on exercise MPI (Table 1). The acute administration
f nifedipine before exercise planar MPI improved perfu-
ion (defined as 20% increase) in approximately one-half
f patients and in one-fourth of segments compared with no
CB administration. The chronic administration of nifed-
pine before exercise planar MPI decreased ischemia, as
videnced by an increase in percent counts in ischemic zones
ompared with no CCB administration (27).
The chronic administration of nifedipine and nicorandil
n 2 separate studies before exercise SPECT reduced the
efect extent (28) and severity (69) and decreased the extent
f ST-segment depression (28).
In summary, the limited available data suggest that CCBs
mprove myocardial perfusion during exercise in patients
ith CAD. The effects on vasodilator MPI have not been
actors That Affect Imagenalysis for Effects of Medications on MPI
Table 5 Factors That Affect ImageAnalysis for Effects of Medications on MPI
A. Serial testing
1. One intervention versus another
2. Before and after intervention
3. Interval testing
4. Single center versus multicenter
B. Issues to be considered
1. Global qualitative
a. Normal
b. Abnormal
i. Scar
ii. Ischemia
2. Global quantitative
a. Total perfusion abnormality
b. Reversible abnormality
c. Extent versus severity
d. Discrete or continuous change
i. Better/worse/same
ii. Percent change
3. Regional quantitative change
a. Total abnormality in each vascular territory
b. Reversible abnormality
C. Factors affecting interpretation
1. Technical
a. Image quality
b. Image protocol
c. Doses of tracers
d. Stress test
2. Biological: day-to-day variation
3. Repeatability
a. Percent abnormal studies
b. Sequential reading
c. Side-by-side reading
i. Biases
ii. Blinded
iii. Visual
iv. Automated
v. Group results versus individual patient
dapted and reprinted with permission from Iskandrian et al. (6).tudied. The same general conclusions may be implied from ghese data on the effects of CCBs on sensitivity of stress
PI as with BB.
ipid-Lowering Agents
xperimental studies. The major cardiovascular benefit of
tatins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhib-
tors) is the inhibition of cholesterol synthesis in the liver.
owever, additional mechanisms for the vascular protective
ffects exist (70–75). Statins improve endothelial function
nd preserve coronary perfusion independent of their reduc-
ion in cholesterol (70–75). They increase smooth muscle
elaxation, decrease oxidative stress, prevent vascular inflam-
ation, decrease inflammatory cell and platelet adhesion to
he endothelial wall, reduce platelet aggregation and throm-
osis, stabilize plaque, and possibly promote angiogenesis (76).
Statins increase nitric oxide bioavailability through the
ctivation of Akt (71,72,77,78). Akt induces endothelial
itrous oxide synthase production and enhances its activity
71,72,77,78). Nitrous oxide synthase decreases myocardial
xygen demand through vasorelaxation and a resultant
eduction in left ventricular wall tension (10,71). Statins also
ncrease vascular smooth muscle relaxation in hyperlipopro-
einemic rabbits and in obese Zucker rats by inhibiting Rho,
small GTP-binding protein (71). Rho enhances phos-
horylation of myosin light chains, which induces myosin–
ctin interaction and smooth muscle cell contraction (71).
Statins stimulate nitric oxide synthase activity, and this
revents the expression of adhesion molecules, cytokines,
nd superoxides inhibiting neutrophilic infiltration and
yocyte injury associated with ischemia and reperfusion
72–74,78). In normocholesterolemic rats, simvastatin pro-
ected against vascular inflammation, and nitric oxide syn-
hase attenuated polymorphonuclear leukocyte adherence
nd minimized capillary plugging by inflammatory cells and
latelets (71–73,78). In fact, polymorphonuclear leukocytes
elease cytotoxic mediators such as oxygen-derived free
adicals, inflammatory cytokines, and proteases (72). Statins
lso stimulate the synthesis of heme oxygenase-1 in macro-
hages, endothelial cells, and vascular smooth muscle cells,
nd heme oxygenase-1 has anti-inflammatory properties
fter ischemia-reperfusion injury, limiting tissue death (79).
tatins also protect against hypoxia in the walls of coronary
rteries by attenuating vasa vasorum neovascularization
ndependent of cholesterol lowering (80). Vasa vasorum are
essels located in the adventitia that provide nourishment to
oronary arteries. Vasa vasorum neovascularization is di-
ectly related to atherosclerosis, and it precedes plaque
rogression (80). Hypercholesterolemia and coronary wall
ypoxia promote the expression of hypoxia-inducible
actor and proangiogenic factors such as matrix metallo-
roteinases and vascular endothelial growth factor in
oronary artery walls.
High-dose atorvastatin improves endothelial dysfunction
n hypercholesterolemic swine without promoting angio-
enesis. Atorvastatin increases phosphorylation of Akt,
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Effects of Medications on Myocardial Perfusion August 5, 2008:401–16lunts the expression of vascular endothelial growth factor,
nd augments the secretion of endostatin, an antiangiogenic
rotein (71). Endostatin prevents endothelial cell growth
nd migration and blunts the secretion of hypoxia-inducible
actor (71). Plaque stability also depends on their collagen
ontent, and statins have been shown to reduce matrix
etalloproteinase expression in atheroma, decrease intimal
mooth muscle cells, and reduce collagen gene expression
70,75). Matrix metalloproteinases are secreted by macro-
hages and weaken the fibrous cap of atherosclerotic plaque,
esulting in plaque rupture (70,75,80). Statins decrease
yocardial no-reflow after ischemia and reperfusion by
pening mitochondrial KATP channels (78,81). There is
vidence that pre-treatment with statins might pre-
ondition and protect against myocardial no-reflow medi-
ted by activation of mitochondrial KATP channels, and
itric oxide plays an integral role in activating these chan-
els (78). By opening mitochondrial KATP channels, the
alance between K uniport and K/H antiport shifts
esulting in a net K uptake. This leads to matrix swelling
nd up-regulates electron transport (78). As a result, mito-
hondrial KATP channel activation improves matrix integ-
ity, promotes mitochondrial membrane depolarization, and
nhibits the production of reactive oxygen species (78).
Independent of lipid-lowering, chronic treatment with
imvastatin preserves myocardial perfusion and coronary
icrovascular integrity as measured by the permeability
ndex (82). Adenosine and dobutamine markedly increased
yocardial perfusion in pigs receiving normal diets and
igh-cholesterol diets with simvastatin (82). In contrast, the
hanges in myocardial perfusion were significantly blunted
n the high-cholesterol group that did not receive statin
herapy (82). During stress, the permeability index was not
hanged in the normal diet or high-cholesterol diet plus
imvastatin group, but the permeability index was signifi-
antly increased in the pigs receiving a high-cholesterol diet
nly (82). These findings suggest that statins improve myo-
ardial perfusion by preserving endothelial function (82).
linical studies. Lipid-lowering medications, particularly
tatins, have been shown to reduce cardiovascular events in
rimary and secondary prevention trials by 24% to 37% (83).
n additional 11% to 21% reduction was achieved with
ntensive high-dose versus moderate-dose statin therapy
84–87). Although statins may produce a regression or
alting of the progression of atherosclerosis as assessed by
oronary angiography and intravascular ultrasound, the
egree of regression is slight compared with the substantial
mprovement in clinical outcomes (88,89). The improved
linical outcomes are likely related to plaque stabilization
nd protection against disruption. Endothelial-dependent
oronary vasodilation abnormalities usually precede clinical
therosclerosis and the development of stenoses on coronary
ngiography and can be assessed by MPI (90,91). The
mpaired endothelial function is mediated by diminished
elease of nitric oxide or its increased metabolism, and the
eduction in nitric oxide leads to impairment of local rhromboprotective mechanisms and promotion of inflam-
ation and vasospasm (92). Statins activate nitric oxide
ynthase expression to increase nitric oxide production and
nhibit endothelin expression to decrease endothelin-1 pro-
uction, a potent vasoconstrictor and promoter of inflam-
ation and atherosclerosis (93). Thus, the effects of statin
herapy on the results of MPI are caused by beneficial effects
n vasomotor abnormalities by improving endothelial integ-
ity and function, decreasing vascular inflammation, im-
roving intrinsic coronary wall elasticity, improving coro-
ary reserve and arterial wall responsiveness to vasodilators,
nd to a lesser extent by mild regression of fixed stenoses
91,94).
ffects of lipid-lowering agents on MBF. The effect of
ipid lowering on the coronary vasomotor response to
cetylcholine (endothelial-dependent vasodilator) or papav-
rine (endothelial-independent vasodilator) was assessed
ith different lipid-lowering agents. Acetylcholine vasocon-
tricts the coronary artery in the presence of endothelial
ysfunction. A cholesterol-lowering diet and cholestyra-
ine for 6 months abolished the acetylcholine-induced
asoconstriction that occurred at baseline before therapy
95). Treatment with pravastatin for 6  3 months amelio-
ated the acetylcholine-induced vasoconstriction of the epi-
ardial arteries that was present at baseline and increased the
oronary blood flow compared with baseline (96). The
esponses to papaverine and nitrates were similar between
he baseline studies and the follow-up studies after treat-
ent with pravastatin, suggesting that the effect of statins is
n endothelial-dependent vasodilation (96). Acetylcholine-
ediated vasodilation was not affected after treatment with
ovastatin for 12 days, but significantly improved after 5.5
onths of treatment with lovastatin compared with baseline
97). The improvement in endothelial function lagged
ehind the improvement of low-density lipoprotein (LDL)
evels that occurred in a matter of days to weeks after
nitiation of therapy. Improvement in acetylcholine-
ediated endothelial vasodilation was also seen after 1 year
f treatment with lovastatin and cholestyramine and with
ovastatin and probuchol (antioxidant effect) (98). The
meliorating effects of lipid lowering on acetylcholine-
ediated vasoconstriction was not seen after treating pa-
ients with mild CAD and mildly elevated lipids with 6
onths of simvastatin (99). However, the results of this
tudy differ from other cited studies, which may be ex-
lained by technical factors, study design, baseline charac-
eristics, differences in lipid-lowering regimens, and other
naccounted medications that may affect endothelial func-
ion. The effects of lipid lowering on endothelial function
ere more pronounced in patients who had more than mild
AD and more than mild lipid abnormalities.
ffects of lipid-lowering therapy on MPI by SPECT. The
lteration in MBF would suggest that lipid-lowering ther-
py and especially statins may have an important effect on
PI. Several studies showed a decrease in the size ofeversible defects by exercise MPI after lipid-lowering
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August 5, 2008:401–16 Effects of Medications on Myocardial Perfusionherapy (Table 2). Treatment with fluvastatin for at least 6
eeks to reach at least 30% LDL lowering decreased the
xercise-induced ischemia that was seen on baseline MPI
100). Compared with baseline, perfusion in ischemic seg-
ents improved by 26% at 12 weeks and by 29% at 24
eeks; no correlation was present between change in LDL
nd change in perfusion (101). The extent and severity of
schemia on exercise MPI improved significantly after treat-
ent with 5 mg simvastatin for 1 year compared with
aseline, whereas it worsened in a group of patients with
imilar baseline characteristics who were treated with pla-
ebo (102). Similar improvement was noted in the resting
erfusion, possibly because of improvement in perfusion of
ibernating or repetitively stunned myocardium (102).
In a study that randomized patients who underwent
uccessful single-vessel percutaneous coronary intervention
PCI) and who had cholesterol 220 mg/dl without treat-
ent to placebo (n  31) or to treatment with 40 mg
ravastatin per day, reversible perfusion defects on exercise
PI occurred in two-thirds of patients of both groups at 2
eeks but became significantly less frequent at 6 months in
he pravastatin group (103). The decrease in LDL corre-
ated with a lower incidence of perfusion defects in the
ravastatin group (r  0.46, p  0.005) (103).
Treatment with pravastatin for 16 weeks improved the
efect size and severity that was seen on baseline dipyrid-
mole MPI (93). Treatment with pravastatin followed by
xercise or adenosine MPI at 6 weeks and 6 months
mproved perfusion defect size from 26 14% at baseline to
5 14% at 6 weeks and to 17 4% at 6 months (p 0.05
s. baseline for both) (104). The stress perfusion improved
n 48% of patients at 6 months (104). This improvement in
PI lagged behind the lowering of LDL levels, and
hanges in lipid levels did not reliably predict changes in
yocardial perfusion at 6 weeks or at 6 months (104).
ffects of lipid-lowering therapy on MPI by PET. The
ffects of lipid lowering on MPI by PET were first studied
y Gould et al. (105) in a study design that included diet
nd lipid-lowering treatment. Serial dipyridamole NH3-
ET studies were performed and assessed quantitatively by
easuring the ratio of stress to rest normalized counts. The
tress defect decreased from 22  20% before to 13  14%
fter treatment (p  0.02) and increased again to 26  22%
fter discontinuation of active treatment. The beneficial
ffects of statins were further confirmed in subsequent
tudies that used dipyridamole or adenosine PET.
Treatment with simvastatin and pravastatin failed to
how improvement in CFR by rubidium PET but not by
-13 ammonia PET, most likely because N-13 ammonia
ET is more accurate than rubidium (105–110) (Table 3).
The effect of intense life-style modification and pharma-
ologic lipid treatment on dipyridamole NH3-PET was
tudied in 409 patients with stable CAD who underwent
tress PET at baseline and after 2.6 years (106). Patients
ere categorized prospectively and blindly into 3 treatment
trategies: 1) poor treatment by diet or lipid drugs, or lontinued active smoking; 2) moderate treatment on the
merican Heart Association diet and lipid-lowering drugs
r a strict low-fat diet (10% of calories) without lipid
rugs; and 3) maximal treatment with diet10% of calories
s fat, regular exercise, and lipid-active drugs dosed to target
oals of LDL 90 mg/dl, high-density lipoprotein 45
g/dl, and triglycerides 100 mg/dl (106). The size and
he severity of the perfusion defect significantly decreased in
he maximal treatment group and increased in the moderate
nd poor treatment groups at 2.6 years of follow-up (p 
.001) (106). However, this study was not randomized, and
edications such as BBs, aspirin, and angiotensin-converting
nzyme inhibitors were different in the 3 groups.
In summary, lipid-lowering medications improve the
erfusion pattern of exercise and vasodilator MPI. This
mprovement may occur as early as 2 months as shown in
ome studies, but occurs more definitely beyond 6 months of
ipid lowering. Because most patients with known or sus-
ected CAD are on statin therapy, it is difficult to ascertain
he relative importance of the other cardiac medications,
specially during vasodilator MPI. The PET quantitative
ata clearly support the notion of improvement in hyper-
mic MBF and even resting MBF (based on patient
election) and provide confirmatory data to the qualitative
PI data by either SPECT or PET.
ffects of Combination
f Antianginal Medications
he effects of combined anti-ischemic medications (BBs,
CBs, nitrates, and stains) were examined in 2 studies, and
oth showed a decrease in perfusion defect size and severity
11,107) (Table 6). Patients who remained clinically stable
ad a greater reduction in ischemic perfusion defect score
13  9%) than those who had a recurrent cardiac event
5 7%; p 0.02). Event-free survival at 12 5 months
as 96% in patients who had a significant (9%) reduction
n perfusion defect score compared with 65% in those who
id not (p  0.009) (107). The hypothesis-generating pilot
tudy by Dakik et al. (107) was the basis for the INSPIRE
Adenosine Sestamibi Post-Infarction Evaluation) trial.
he INSPIRE trial. The INSPIRE trial prospectively
andomized 205 stable survivors of acute myocardial infarc-
ion to a strategy of intensive medical therapy compared
ith revascularization for the suppression of adenosine-
nduced ischemia on MPI (108). All patients had large total
20%) and reversible perfusion defects (10%) and left
entricular ejection fraction 35%. Patients were then
andomized to a strategy of intensive anti-ischemic medical
herapy (group 1) or a strategy of coronary angiography with
he intent of revascularization (group 2). Baseline and
ollow-up adenosine MPI studies were performed at a
edian of 10 and 62 days after myocardial infarction,
espectively. Cross-over from medical therapy to revascular-
zation occurred in 26% of patients and from the revascu-
arization strategy to medical therapy in 23% of patients. Of
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and 36% in group 2 were on 2 or more antianginal
edications (p  0.05). Significant reductions in reversible
efect size (15  9% vs. 16.2  9%; p  NS) and total
efect size (16.2  10% vs. 17.8  12%; p  NS) were
oted in groups 1 and 2, respectively. The incidence of
eath or nonfatal reinfarction at 1 year was 7.9% in group 1
nd 6.7% in group 2 (p  NS) (108). Of note, lipid-
owering therapy was used in both groups. An example of
he effects of combination therapy is shown in Figure 1.
he COURAGE nuclear substudy. The nuclear substudy
f the COURAGE (Results from Clinical Outcomes Uti-
Figure 1 Baseline and Follow-Up Stress/Rest SPECT Sestamib
(A) A patient’s baseline stress/rest SPECT sestamibi perfusion images showing la
images and the bottom rows show rest images. (B) Polar maps estimated the ext
ejection fraction was 62% by gated SPECT. (C) SPECT sestamibi MPI at 6-month f
ischemia (same format as A) is less. (D) Polar maps estimated extent of total abn
was 67%. HLA  horizontal long axis; MPI  myocardial perfusion imaging; SAX 
long axis.
ummary of Studies That Evaluated the Effects of Combination Ant
Table 6 Summary of Studies That Evaluated the Effects of Com
Author, Year (Ref. #) Patients Treatmen
Sharir et al., 1998 (11) 26 patients with1 reversible
perfusion defects on first
dipyridamole Tl-SPECT study
while off antianginal
medications underwent a
second dipyridamole
Tl-SPECT on antianginal
medications
Off antianginal med
48 h for CCB and B
at least 24 h for
On antianginal med
CCB (81%), nitrates
(31%), and 1 a
medication (77%
Dakik et al., 1998 (107) 44 stable survivors of acute MI
who had a large total
(20% of left ventricular
myocardium) and ischemic
(10%) perfusion defect
size on baseline adenosine
Tl-SPECT
Maximum tolerated
metoprolol, nitra
diltiazem: 73% w
on 2 and 27% o
3 medications
PCI : 16% were on
maximal antiang
medication
Randomized study
B  beta-blocker; CCB  calcium-channel blocker; other abbreviations as in Tables 1 and 2.izing Revascularization and Aggressive Guideline-Driven
rug Evaluation) trial recruited 159 patients who were
reated with PCI plus optimal medical therapy and 155
atients who were treated with optimal medical therapy
lone (2). The patients had a baseline stress MPI and a
epeat stress MPI after 6 to 18 months of treatment. The
esults showed that PCI added to optimal medical treat-
ent was more effective in reducing ischemia and improv-
ng angina than optimal medical treatment alone, particu-
arly in patients with moderate-to-severe pre-treatment
schemia. Improvement in the ischemic burden on stress
PI occurred in 33% of patients in the PCI plus optimal
After Medical Therapy
chemia of the left anterior descending artery territory; the top rows show stress
total ischemia to be 31% of left ventricular myocardium. The left ventricular
p with maximal medical therapy including statin, beta-blockers, and nitrates. The
ity to be 21%, ischemia 16%, and scar 5%. The left ventricular ejection fraction
axis; SPECT  single-photon emission computed tomography; VLA  vertical
nal Medications on Stress SPECT
tion Antianginal Medications on Stress SPECT
Testing Perfusion
ns:
for
s
s:
), BB
inal
Off antianginal medications
On antianginal medications
SSS  24  10; SRS  15  8
SSS  9  11; SRS  11  9
(p  0.01 for summed stress score
and 0.04 for summed rest score)
of
d Baseline vs. intensive
medical therapy
Baseline vs. PCI: 19 patients
(treatment test performed
at 43  26 days from
baseline test)
Total perfusion/ischemic defect size (%)
38  13/22  12 to 26  16/10 
10 (p  0.0001)
35  12/18  6 to 20  16/6  7
(p  0.0001)i MPI
rge is
ent of
ollow-u
ormal
shortiangi
bina
t
icatio
B and
nitrate
ication
(73%
ntiang
)
doses
tes, an
ere
n
any
inal
m
o
m
i
h
m
d
a
r
r
a
n
m
I
o
T
C
M
s
e
A
t
n
o
t
t
u
m
c
M
t
d
s
m
u
e
u
i
c
m
I
C
r
g
R
D
B
A
R
413JACC Vol. 52, No. 6, 2008 Zoghbi et al.
August 5, 2008:401–16 Effects of Medications on Myocardial Perfusionedical therapy arm, compared with 19% of patients in the
ptimal medical therapy alone group (2). Patients with
oderate to severe pre-treatment ischemia had a 78%
mprovement in ischemia, compared with 52% in those who
ad mild pretreatment ischemia (p  0.007) (2). Further-
ore, ischemia reduction was associated with a lower risk of
eath/myocardial infarction, whereas residual ischemia was
ssociated with a higher risk of death/myocardial infarction
egardless of the mode of treatment (2). There was a graded
elationship between event risk and residual ischemia extent
nd severity. Death or MI occurred in 0% of patients with
o ischemia and in 39.3% of patients with 10% ischemic
yocardium on follow-up MPI (2).
mplications of Use
f Cardiac Medications in Stress MPI
he cumulative data show that nitrates, first-generation
CBs, BBs, and especially statins modify results of stress
PI (especially exercise) by decreasing the extent and
everity of reversible ischemia or even by eliminating isch-
mia completely in some patients. Nevertheless, the current
merican College of Cardiology/American Heart Associa-
ion guidelines recommend that cardiac medications should
ot be discontinued before stress testing because of the fear
f ischemic events (109,110). Furthermore, it is unlikely
hat discontinuation of statins for a day or two would nullify
he protective effects. It should be noted that in research,
nlike clinical studies, most of these medications are used in
aximally tolerated doses. The effect of smaller doses is not
lear, but it would presumably be less evident. The SPECT
PI appropriateness criteria and guidelines (111) suggest
hat stress MPI is most beneficial in patients with interme-
iate pre-test likelihood of CAD, and hence conceivably in
uch patients the detection of CAD, especially those with
ild ischemia, may be masked by such medications or
nderestimated. For diagnostic purposes, it might be nec-
ssary to repeat the test after all medications are discontin-
ed for a reasonable amount of time. On the other hand, the
nformation provided by MPI while patients are on medi-
ations provides powerful prognostic data, as shown from
ultiple databases as well as prospective studies such as
NSPIRE (in patients with acute coronary syndromes) and
OURAGE (in patients with stable CAD). As such,
esults of stress MPI can be used to monitor therapy and
auge its success.
eprint requests and correspondence: Dr. Todd A. Dorfman,
ivision of Cardiovascular Diseases, The University of Alabama–
irmingham, LHRB 306, 1530 3rd Avenue South, Birmingham,
labama 35294-0007. E-mail: tdorfman@cardmail.dom.uab.edu.
EFERENCES1. Iskandrian A, Garcia E. Nuclear Cardiac Imaging: Principles and
Applications. 4th edition. England: Oxford University Press, 2008.2. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy
with or without percutaneous coronary intervention to reduce isch-
emic burden: results from the Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation (COURAGE) trial nu-
clear substudy. Circulation 2008;117:1283–91.
3. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guide-
lines for the clinical use of cardiac radionuclide imaging—executive
summary: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (ACC/AHA/
ASNC Committee to Revise the 1995 Guidelines for the Clinical
Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003;42:
1318–33.
4. Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS. Stress proto-
cols and tracers. J Nucl Cardiol 2006;13:e80–90.
5. Hansen CL, Goldstein RA, Akinboboye OO, et al. Myocardial
perfusion and function: single photon emission computed tomogra-
phy. J Nucl Cardiol 2007;14:e39–60.
6. Iskandrian AE, Garcia EV, Faber T. Analysis of serial images: a
challenge and an opportunity. J Nucl Cardiol 2008;15:23–6.
7. Golub RJ, Ahlberg AW, McClellan JR, et al. Interpretive reproduc-
ibility of stress Tc-99m sestamibi tomographic myocardial perfusion
imaging. J Nucl Cardiol 1999;6:257–69.
8. Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW.
Interobserver variability in coronary angiography. Circulation 1976;
53:627–32.
9. Harrison DG, Bates JN. The nitrovasodilators. New ideas about old
drugs. Circulation 1993;87:1461–7.
10. Katzung B, Chatterjee K. Basic and Clinical Pharmacology. 7th
edition. Stamford, CT: Appleton and Lange, 1998.
11. Sharir T, Rabinowitz B, Livschitz S, et al. Underestimation of extent
and severity of coronary artery disease by dipyridamole stress
thallium-201 single-photon emission computed tomographic myo-
cardial perfusion imaging in patients taking antianginal drugs. J Am
Coll Cardiol 1998;31:1540–6.
12. Sabharwal NK, Lahiri A. Antianginal medications and diagnostic
accuracy of myocardial perfusion imaging. J Nucl Cardiol 2003;10:
433–5.
13. Habazettl H, Vollmar B, Christ M, Baier H, Conzen PF, Peter K.
Heterogeneous microvascular coronary vasodilation by adenosine and
nitroglycerin in dogs. J Appl Physiol 1994;76:1951–60.
14. Bottcher M, Madsen MM, Randsbaek F, et al. Effect of oral
nitroglycerin and cold stress on myocardial perfusion in areas sub-
tended by stenosed and nonstenosed coronary arteries. Am J Cardiol
2002;89:1019–24.
15. Macho P, Vatner SF. Effects of nitroglycerin and nitroprusside on
large and small coronary vessels in conscious dogs. Circulation
1981;64:1101–7.
16. Feldman RL, Marx JD, Pepine CJ, Conti CR. Analysis of coronary
responses to various doses of intracoronary nitroglycerin. Circulation
1982;66:321–7.
17. Kanatsuka H, Eastham CL, Marcus ML, Lamping KG. Effects of
nitroglycerin on the coronary microcirculation in normal and isch-
emic myocardium. J Cardiovasc Pharmacol 1992;19:755–63.
18. Cohen MV, Downey JM, Sonnenblick EH, Kirk ES. The effects of
nitroglycerin on coronary collaterals and myocardial contractility.
J Clin Invest 1973;52:2836–47.
19. Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion
inhibits cyclic blood flow responses caused by periodic platelet
thrombus formation in stenosed canine coronary arteries. Circulation
1991;83:2122–7.
20. Karlberg KE, Torfgard K, Ahlner J, Sylven C. Dose-dependent effect
of intravenous nitroglycerin on platelet aggregation, and correlation
with plasma glyceryl dinitrate concentration in healthy men. Am J
Cardiol 1992;69:802–5.
21. Salvemini D, Currie MG, Mollace V. Nitric oxide-mediated cyclo-
oxygenase activation. A key event in the antiplatelet effects of
nitrovasodilators. J Clin Invest 1996;97:2562–8.
22. Lacoste LL, Theroux P, Lidon RM, Colucci R, Lam JY. Antithrom-
botic properties of transdermal nitroglycerin in stable angina pectoris.
Am J Cardiol 1994;73:1058–62.
23. Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerin tolerance at
the platelet level in patients with angina pectoris. Am J Cardiol
1997;80:128–31.
414 Zoghbi et al. JACC Vol. 52, No. 6, 2008
Effects of Medications on Myocardial Perfusion August 5, 2008:401–1624. Aoki M, Sakai K, Koyanagi S, Takeshita A, Nakamura M. Effect of
nitroglycerin on coronary collateral function during exercise evaluated
by quantitative analysis of thallium-201 single photon emission
computed tomography. Am Heart J 1991;121:1361–6.
25. Goller V, Clausen M, Henze E, et al. Reduction of exercise-induced
myocardial perfusion defects by isosorbide-5-nitrate: assessment us-
ing quantitative Tc-99m-MIBI-SPECT. Coron Artery Dis 1995;6:
245–9.
26. Lewin HC, Hachamovitch R, Harris AG, et al. Sustained reduction
of exercise perfusion defect extent and severity with isosorbide
mononitrate (Imdur) as demonstrated by means of technetium 99m
sestamibi. J Nucl Cardiol 2000;7:342–53.
27. Stegaru B, Loose R, Keller H, Buss J, Wetzel E. Effects of long-term
treatment with 120 mg of sustained-release isosorbide dinitrate and
60 mg of sustained-release nifedipine on myocardial perfusion. Am J
Cardiol 1988;61:74E–7E.
28. Eldridge JE, Burdick DC, Jones RH, Hossack KF. Comparison of
nitroglycerin patches and nifedipine. J Cardiovasc Pharmacol 1987;
10:315–9.
29. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitro-
glycerin patch therapy reduces the extent of exercise-induced myo-
cardial ischemia: results of a double-blind, placebo-controlled trial
using quantitative thallium-201 tomography. J Am Coll Cardiol
1994;24:25–32.
30. Sciagra R. Nitrates and viability: a durable affair. J Nucl Med
2003;44:752–5.
31. Tadamura E, Mamede M, Kubo S, et al. The effect of nitroglycerin
on myocardial blood flow in various segments characterized by
rest-redistribution thallium SPECT. J Nucl Med 2003;44:745–51.
32. Slart RH, Agool A, van Veldhuisen DJ, Dierckx RA, Bax JJ. Nitrate
administration increases blood flow in dysfunctional but viable
myocardium, leading to improved assessment of myocardial viability:
a PET study. J Nucl Med 2006;47:1307–11.
33. Bisi G, Sciagra R, Santoro GM, Fazzini PF. Rest technetium-99m
sestamibi tomography in combination with short-term administra-
tion of nitrates: feasibility and reliability for prediction of postrevas-
cularization outcome of asynergic territories. J Am Coll Cardiol
1994;24:1282–9.
34. Bisi G, Sciagra R, Santoro GM, Rossi V, Fazzini PF. Technetium-
99m-sestamibi imaging with nitrate infusion to detect viable hiber-
nating myocardium and predict postrevascularization recovery. J Nucl
Med 1995;36:1994–2000.
35. Flotats A, Carrio I, Estorch M, et al. Nitrate administration to
enhance the detection of myocardial viability by technetium-99m
tetrofosmin single-photon emission tomography. Eur J Nucl Med
1997;24:767–73.
36. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM.
Accuracy of currently available techniques for prediction of functional
recovery after revascularization in patients with left ventricular
dysfunction due to chronic coronary artery disease: comparison of
pooled data. J Am Coll Cardiol 1997;30:1451–60.
37. He ZX, Yang MF, Liu XJ, et al. Association of myocardial viability
on nitrate-augmented technetium-99m hexakis-2-methoxylisobutyl
isonitrile myocardial tomography and intermediate-term outcome in
patients with prior myocardial infarction and left ventricular dysfunc-
tion. Am J Cardiol 2003;92:696–9.
38. Kula M, Tutus A, Unal S, Topsakal R, Ergin A. Technetium-99m-
tetrofosmin imaging with incremental nitroglycerin infusion to detect
severely ischaemic but viable myocardium: a comparative study with
thallium-201. Nucl Med Commun 2003;24:987–94.
39. Djaballah W, Muller MA, Angioi M, et al. Nitrate-enhanced gated
SPECT in patients with primary angioplasty for acute myocardial
infarction: evidence of a reversible and nitrate-sensitive impairment
of myocardial perfusion. Eur J Nucl Med Mol Imaging 2007;34:
1981–90.
40. Sorrentino AR, Acampa W, Petretta M, Mainolfi C, Salvatore M,
Cuocolo A. Comparison of the prognostic value of SPECT after
nitrate administration and metabolic imaging by PET in patients
with ischaemic left ventricular dysfunction. Eur J Nucl Med Mol
Imaging 2007;34:558–62.
41. Guth BD, Heusch G, Seitelberger R, Ross J, Jr. Mechanism of
beneficial effect of beta-adrenergic blockade on exercise-induced
myocardial ischemia in conscious dogs. Circ Res 1987;60:738–46.42. Koepfli P, Wyss CA, Namdar M, et al. Beta-adrenergic blockade and
myocardial perfusion in coronary artery disease: differential effects in
stenotic versus remote myocardial segments. J Nucl Med 2004;45:
1626–31.
43. Grover GJ, Weiss HR, Kostis JB, Li JK, Kovacs T, Kedem J.
Beta-adrenoceptor stimulation and blockade during myocardial isch-
emia in dogs: effect on cardiac O2 supply and consumption. Eur
J Pharmacol 1987;142:103–13.
44. Matsuzaki M, Patritti J, Tajimi T, Miller M, Kemper WS, Ross J,
Jr.Effects of beta-blockade on regional myocardial flow and function
during exercise. Am J Physiol 1984;247:H52–60.
45. Zmudka K, Dubiel J, Pieniazek P, et al. Influence of an early
adrenergic blockade on thrombotic infarct size and myocardial
metabolism. J Physiol Pharmacol 1998;49:333–52.
46. Liu XK, Engelman RM, Agrawal HR, Das DK. Preservation of
membrane phospholipids by propranolol, pindolol, and metoprolol: a
novel mechanism of action of beta-blockers. J Mol Cell Cardiol
1991;23:1091–100.
47. Monteiro P, Duarte AI, Moreno A, Goncalves LM, Providencia LA.
Carvedilol improves energy production during acute global myocar-
dial ischaemia. Eur J Pharmacol 2003;482:245–53.
48. Schwarz ER, Kersting PH, Reffelmann T, et al. Cardioprotection by
carvedilol: antiapoptosis is independent of beta-adrenoceptor block-
age in the rat heart. J Cardiovasc Pharmacol Ther 2003;8:207–15.
49. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial
protection by the novel vasodilating beta-blocker, carvedilol: potential
relevance of anti-oxidant activity. J Hypertens 1993;11 Suppl:S41–8.
50. Hockings B, Saltissi S, Croft DN, Webb-Peploe MM. Effect of beta
adrenergic blockade on thallium-201 myocardial perfusion imaging.
Br Heart J 1983;49:83–9.
51. Martin GJ, Henkin RE, Scanlon PJ. Beta blockers and the sensitivity
of the thallium treadmill test. Chest 1987;92:486–7.
52. Rainwater J, Steele P, Kirch D, LeFree M, Jensen D, Vogel R. Effect
of propranolol on myocardial perfusion images and exercise ejection
fraction in men with coronary artery disease. Circulation 1982;65:
77–81.
53. Steele P, Sklar J, Kirch D, Vogel R, Rhodes CA. Thallium-201
myocardial imaging during maximal and submaximal exercise: com-
parison of submaximal exercise with propranolol. Am Heart J
1983;106:1353–7.
54. Narahara KA, Thompson CJ, Hazen JF, Brizendine M, Mena I. The
effect of beta blockade on single photon emission computed tomo-
graphic (SPECT) thallium-201 images in patients with coronary
disease. Am Heart J 1989;117:1030–5.
55. Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute
propranolol administration on dobutamine-induced myocardial isch-
emia as evaluated by myocardial perfusion imaging and echocardiog-
raphy. Am J Cardiol 1997;80:268–72.
56. Bridges AB, Kennedy N, McNeill GP, Cook B, Pringle TH. The
effect of atenolol on dipyridamole 201Tl myocardial perfusion to-
mography in patients with coronary artery disease. Nucl Med
Commun 1992;13:41–6.
57. Taillefer R, Ahlberg AW, Masood Y, et al. Acute beta-blockade
reduces the extent and severity of myocardial perfusion defects with
dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol
2003;42:1475–83.
58. Bottcher M, Czernin J, Sun K, Phelps ME, Schelbert HR. Effect of
beta 1 adrenergic receptor blockade on myocardial blood flow and
vasodilatory capacity. J Nucl Med 1997;38:442–6.
59. Billinger M, Seiler C, Fleisch M, Eberli FR, Meier B, Hess OM. Do
beta-adrenergic blocking agents increase coronary flow reserve? J Am
Coll Cardiol 2001;38:1866–71.
60. Bottcher M, Refsgaard J, Madsen MM, et al. Effect of antianginal
medication on resting myocardial perfusion and pharmacologically
induced hyperemia. J Nucl Cardiol 2003;10:345–52.
61. Zervos G, Zusman RM, Swindle LA, Alpert NM, Fischman AJ,
Gewirtz H. Effects of nifedipine on myocardial blood flow and
systolic function in humans with ischemic heart disease. Coron
Artery Dis 1999;10:185–94.
62. Pepine CJ. The role of calcium antagonists in ischaemic heart disease.
Eur Heart J 1995;16 Suppl H:19–24.
63. Tillmanns H, Neumann FJ, Parekh N, et al. Calcium antagonists and
myocardial microperfusion. Drugs 1991;42 Suppl 1:1–6.
11
1
1
1
1
1
415JACC Vol. 52, No. 6, 2008 Zoghbi et al.
August 5, 2008:401–16 Effects of Medications on Myocardial Perfusion64. Reimer KA, Jennings RB. Effects of calcium-channel blockers on
myocardial preservation during experimental acute myocardial infarc-
tion. Am J Cardiol 1985;55:107B–15B.
65. Sassen LM, Bezstarosti K, Verdouw PD, Lamers JM. Effects of
nisoldipine on recovery of coronary blood flow, sarcoplasmic reticu-
lum function and other biochemical parameters in post-ischaemic
porcine myocardium. Biochem Pharmacol 1991;41:43–51.
66. Park SW, Tang XL, Qiu Y, Sun JZ, Bolli R. Nisoldipine attenuates
myocardial stunning induced by multiple coronary occlusions in
conscious pigs and this effect is independent of changes in hemody-
namics or coronary blood flow. J Mol Cell Cardiol 1996;28:655–66.
67. Folts JD. Inhibition of platelet activity in vivo by amlodipine alone
and combined with aspirin. Int J Cardiol 1997;62 Suppl 2:S111–7.
68. Ehring T, Heusch G. Dihydropyridine calcium antagonists: benefi-
cial or adverse effects in the setting of myocardial ischaemia/
reperfusion? Cardiology 1997;88 Suppl 1:3–14, discussion 15–6.
69. Yamazaki J, Ohsawa H, Uchi T, et al. Study of the efficacy of
nicorandil in patients with ischaemic heart disease using Exercise-
T1-201 myocardial tomography. Eur J Clin Pharmacol 1993;44:
211–7.
70. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibi-
tors reduce MMP-9 secretion by macrophages. Arterioscler Thromb
Vasc Biol 1998;18:1671–8.
71. Boodhwani M, Nakai Y, Voisine P, et al. High-dose atorvastatin
improves hypercholesterolemic coronary endothelial dysfunction
without improving the angiogenic response. Circulation 2006;114:
I402–8.
72. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ.
Simvastatin preserves the ischemic-reperfused myocardium in nor-
mocholesterolemic rat hearts. Circulation 1999;100:178–84.
73. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA
reductase inhibitor, protects ischemic reperfused myocardium in
normocholesterolemic rats. J Cardiovasc Pharmacol 2003;41:649–56.
74. Cowled PA, Khanna A, Laws PE, Field JB, Varelias A, Fitridge RA.
Statins inhibit neutrophil infiltration in skeletal muscle reperfusion
injury. J Surg Res 2007;141:267–76.
75. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle
cell accumulation and collagen content in established atheroma of
Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:
993–9.
76. Herman AG, Moncada S. Therapeutic potential of nitric oxide
donors in the prevention and treatment of atherosclerosis. Eur
Heart J 2005;26:1945–55.
77. Jones SP, Gibson MF, Rimmer DM 3rd, Gibson TM, Sharp BR,
Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin,
a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002;40:
1172–8.
78. Calvert JW, Lefer DJ. Statin therapy and myocardial no-reflow. Br J
Pharmacol 2006;149:229–31.
79. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia-
reperfusion injury by inducing heme oxygenase-1 in infiltrating
macrophages. Am J Pathol 2007;170:1192–9.
80. Wilson SH, Herrmann J, Lerman LO, et al. Simvastatin preserves
the structure of coronary adventitial vasa vasorum in experimental
hypercholesterolemia independent of lipid lowering. Circulation
2002;105:415–8.
81. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with
simvastatin reduces myocardial no-reflow by opening mitochondrial
K(ATP) channel. Br J Pharmacol 2006;149:243–9.
82. Bonetti PO, Wilson SH, Rodriguez-Porcel M, Holmes DR Jr.,
Lerman LO, Lerman A. Simvastatin preserves myocardial perfusion
and coronary microvascular permeability in experimental hypercho-
lesterolemia independent of lipid lowering. J Am Coll Cardiol
2002;40:546–54.
83. Gotto AM, Jr. Review of primary and secondary prevention trials
with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96:
34F–8F.
84. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med 2004;350:1495–504.
85. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering
with atorvastatin in patients with stable coronary disease. N Engl
J Med 2005;352:1425–35.86. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a
delayed conservative simvastatin strategy in patients with acute
coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:
1307–16.
87. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorva-
statin vs usual-dose simvastatin for secondary prevention after myo-
cardial infarction: the IDEAL study: a randomized controlled trial.
JAMA 2005;294:2437–45.
88. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery
disease of lipid-lowering diet, or diet plus cholestyramine, in the St
Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992;
339:563–9.
89. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery
disease as a result of intensive lipid-lowering therapy in men with
high levels of apolipoprotein B. N Engl J Med 1990;323:1289–98.
90. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response
to acetylcholine relates to risk factors for coronary artery disease.
Circulation 1990;81:491–7.
91. Schwartz RG. Beyond the cholesterol profile: monitoring therapeutic
effectiveness of statin therapy. J Nucl Cardiol 2001;8:528–32.
92. Furchgott RF. Endothelium-derived relaxing factor: discovery, early
studies, and identification as nitric oxide. Biosci Rep 1999;19:235–51.
93. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction
improves myocardial perfusion abnormalities in patients with coro-
nary artery disease and average cholesterol levels. J Am Coll Cardiol
2000;35:76–82.
94. Shaw LJ, Berman DS. Sequential single-photon emission computed
tomography myocardial perfusion imaging. Am J Cardiol 2005;96:
28J–39J.
95. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-
lowering therapy on coronary endothelium-dependent relaxation in
hypercholesterolaemic patients. Lancet 1993;341:1496–500.
96. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol
with pravastatin improves endothelium-dependent coronary vasomo-
tion in patients with hypercholesterolemia. Circulation 1994;89:
2519–24.
97. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of
cholesterol-lowering therapy on the coronary endothelium in patients
with coronary artery disease. N Engl J Med 1995;332:481–7.
98. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P.
The effect of cholesterol-lowering and antioxidant therapy on
endothelium-dependent coronary vasomotion. N Engl J Med 1995;
332:488–93.
99. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-
lowering therapy on coronary endothelial vasomotor function in
patients with coronary artery disease. Circulation 2000;102:846–51.
00. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger
G. Improvement of myocardial perfusion by short-term fluvastatin
therapy in coronary artery disease. Am J Cardiol 1995;76:122A–5A.
01. Eichstadt HW, Abletshauser CB, Stork T, Weidinger G. Beneficial
effects of fluvastatin on myocardial blood flow at two time-points in
hypercholesterolemic patients with coronary artery disease. J Cardio-
vasc Pharmacol 2000;35:735–40.
02. Hosokawa R, Nohara R, Linxue L, et al. Effect of long-term
cholesterol-lowering treatment with HMG-CoA reductase inhib-
itor (simvastatin) on myocardial perfusion evaluated by thallium-
201 single photon emission computed tomography. Jpn Circ J
2000;64:177–82.
03. Manfrini O, Pizzi C, Morgagni G, Fontana F, Bugiardini R. Effect
of pravastatin on myocardial perfusion after percutaneous translumi-
nal coronary angioplasty. Am J Cardiol 2004;93:1391–3.
04. Schwartz RG, Pearson TA, Kalaria VG, et al. Prospective serial
evaluation of myocardial perfusion and lipids during the first six
months of pravastatin therapy: coronary artery disease regression
single photon emission computed tomography monitoring trial. J Am
Coll Cardiol 2003;42:600–10.
05. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol
lowering decreases size and severity of perfusion abnormalities by
positron emission tomography after dipyridamole in patients with
coronary artery disease. A potential noninvasive marker of healing
coronary endothelium. Circulation 1994;89:1530–8.
06. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense
lifestyle and pharmacologic lipid treatment further reduce coronary
events and myocardial perfusion abnormalities compared with usual-
11
1
1
1
1
1
1
1
1
1
1
K
416 Zoghbi et al. JACC Vol. 52, No. 6, 2008
Effects of Medications on Myocardial Perfusion August 5, 2008:401–16care cholesterol-lowering drugs in coronary artery disease. J Am Coll
Cardiol 2003;41:263–72.
07. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy
versus coronary angioplasty for suppression of myocardial ischemia in
survivors of acute myocardial infarction: a prospective, randomized
pilot study. Circulation 1998;98:2017–23.
08. Mahmarian JJ, Dakik HA, Filipchuk NG, et al. An initial strategy of
intensive medical therapy is comparable to that of coronary revascu-
larization for suppression of scintigraphic ischemia in high-risk but
stable survivors of acute myocardial infarction. J Am Coll Cardiol
2006;48:2458–67.
09. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for
exercise testing. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260–
311.
10. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline
update for exercise testing: summary article. A report of the American
College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee to Update the 1997 Exercise Test-
ing Guidelines). J Am Coll Cardiol 2002;40:1531–40.
11. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
guideline update for the management of patients with chronic stable
angina—summary article: a report of the American College of
Cardiology/American Heart Association Task Force on practice
guidelines (Committee on the Management of Patients With
Chronic Stable Angina). J Am Coll Cardiol 2003;41:159–68.
12. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H.
Effects of short-term treatment of hyperlipidemia on coronary vaso- cdilator function and myocardial perfusion in regions having
substantial impairment of baseline dilator reverse. Circulation
1998;98:1291–6.
13. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R,
Lehmann J. Improvement in coronary flow reserve determined by
positron emission tomography after 6 months of cholesterol-lowering
therapy in patients with early stages of coronary atherosclerosis.
Circulation 1999;99:2871–5.
14. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W,
Schwaiger M. Delayed response of myocardial flow reserve to
lipid-lowering therapy with fluvastatin. Circulation 1999;99:475–81.
15. Yokoyama I, Momomura S, Ohtake T, et al. Improvement of
impaired myocardial vasodilatation due to diffuse coronary athero-
sclerosis in hypercholesterolemics after lipid-lowering therapy. Cir-
culation 1999;100:117–22.
16. Yokoyama I, Yonekura K, Inoue Y, Ohtomo K, Nagai R. Long-term
effect of simvastatin on the improvement of impaired myocardial flow
reserve in patients with familial hypercholesterolemia without gender
variance. J Nucl Cardiol 2001;8:445–51.
17. Ling MC, Ruddy TD, deKemp RA, et al. Early effects of statin
therapy on endothelial function and microvascular reactivity in
patients with coronary artery disease. Am Heart J 2005;149:1137.
18. Muller S, Konig I, Meyer W, Kojda G. Inhibition of vascular
oxidative stress in hypercholesterolemia by eccentric isosorbide
mononitrate. J Am Coll Cardiol 2004;44:624–31.
ey Words: myocardial perfusion imaging y beta-blockers y calcium-
hannel blockers y lipid-lowering medications y SPECT.
